This single-center, randomized, double-blind, placebo-controlled study will evaluate the
effect of aleglitazar on insulin sensitivity in patients with type 2 diabetes mellitus who
are inadequately controlled on metformin monotherapy. Patients will be randomized to receive
either aleglitazar 150 mcg or placebo orally daily for 16 weeks, in addition to their
existing dose and regimen of metformin.